🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    approved small molecule active

    3 trials

  2. Standard clinical care first, followed by standard clinical care and varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    approved small molecule completed

    1 trial

  3. Subcutaneous glargine insulin

    Lxo Ireland Designated Activity Company

    Diabetes Mellitus

    approved small molecule completed

    1 trial

  4. Sugammadex hameln 100 mg/ml oplossing voor injectie, Naloxon HCl Accord 0,4 mg/ml, oplossing voor injectie / infusie in een voorgevulde spuit, ANEXATE 0,5 mg/5 ml, solution injectable (I.V.), REMIMAZOLAM , Sufentanil Viatris 5 microgram/ml oplossing voor injectie, Esmeron 10 mg/ml, oplossing voor injectie

    Disc Medicine

    General anesthesia

    approved small molecule active

    1 trial

  5. Sulfato de Magnesio Altan 150 mg/ml solución inyectable y para perfusión EFG, LIDOCAINE HYDROCHLORIDE, Dexdor 100 micrograms/ml concentrate for solution for infusion, KETOLAR 50 mg/ml solución inyectable.

    The George Institute

    Obesity

    approved small molecule active

    1 trial

  6. Surabgene Lomparvovec (ABBV-RGX-314), Lucentis 10 mg/ml solution for injection in pre-filled syringe, Surabgene Lomparvovec (ABBV-RGX-314)

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    approved small molecule active

    1 trial

  7. TAGRISSO 80 mg film-coated tablets

    Disc Medicine

    EGFR mutated locally advanced or metastatic non-small cell lung cancer

    approved small molecule active

    1 trial

  8. TAGRISSO 80 mg film-coated tablets

    Disc Medicine

    EGFR mutated locally advanced or metastatic non-small cell lung cancer

    approved small molecule active

    1 trial

  9. TAGRISSO 80 mg film-coated tablets

    Fondazione Telethon ETS

    Patients with EGFR mutant NSCLC according to TP53 mutational status

    approved small molecule active

    1 trial

  10. TESTOGEL 50 mg gel transdérmico en sobres, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    approved small molecule active

    1 trial

  11. TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, Mekinist 2 mg film-coated tablets, DRB436, DRB436, DRB436, TMT212

    Novartis Pharmaceuticals

    Multiple indications

    approved small molecule active

    1 trial

  12. TRALOKINUMAB, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Atopic dermatitis and moderate-to severe atopic hand eczema

    approved small molecule active

    1 trial

  13. TYRX™ Absorbable Antibacterial Envelope

    Rhythm Pharmaceuticals Netherlands B.V.

    CIED Related Infection

    approved other completed

    1 trial

  14. Telmisartan/Amlodipine/Hydrochlorothiazide, Teldipin, 80 mg + 5 mg, tabletki, Telmisartan/Amlodipine/Hydrochlorothiazide, Tamloset 40 mg/5 mg tabletta, Tamloset 80 mg/10 mg tabletta, Telassmo 80 mg/10 mg tablete, Tamloset 80 mg/5 mg tabletta, Teldipin, 80 mg + 10 mg, tabletki, Telassmo 40 mg/5 mg tablete, Telmisartan/Amlodipine/Hydrochlorothiazide, Teldipin, 40 mg + 5 mg, tabletki, Telassmo 80 mg/5 mg tablete

    Novo Nordisk A/S

    Arterial hypertension

    approved small molecule active

    1 trial

  15. Tenofovir Alafenamide Tablets

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    approved small molecule active

    1 trial

  16. Tenofovir Alafenamide fumarate 25mg Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Hepatitis B

    approved small molecule active

    1 trial

  17. The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.

    Pierre Fabre Australia Pty Ltd

    Chronic Obstructive Pulmonary Disease

    approved other active

    1 trial

  18. The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

  19. The placebo has the same composition as the investigational medicinal product alkacitrat effervescent tablet 2 g/tab (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., ALKACITRAT Αναβράζον δισκίο 2 g/tab

    Lacuna Pharma Pty Ltd

    Functional Dyspepsia

    approved small molecule active

    1 trial

  20. Ticagrelor followed with Methoxyflurane

    COLLEGIUM PHARMACEUTICAL, INC

    Unstable Angina

    approved small molecule completed

    1 trial

  21. Tirzepatide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  22. Tislelizumab

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    approved small molecule active

    1 trial

  23. Tislelizumab + cisplatin + paclitaxel

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  24. Tocilizumab

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources